Ad
related to: fda indications for modafinil 5 mg pill new appearance 2024goodrx.com has been visited by 100K+ users in the past month
- Healthcare Professionals
GoodRx® Can Help You Get Major
Savings For Your Patients
- Our Social Impact Mission
At GoodRx, values matter. Visit us
to see how we make a difference.
- Do I Need Insurance?
No! Compare Our Prices to Your
Insurance & Get the Biggest Savings
- Find A Pharmacy Near Me
Search & Compare the Lowest Prices
to Save at Your Favorite Pharmacy
- Healthcare Professionals
Search results
Results from the WOW.Com Content Network
Unlike modafinil, adrafinil does not have FDA approval and was withdrawn from the French market in 2011. [169] The FDA approved modafinil in 1998 for narcolepsy treatment, and later for shift work sleep disorder and obstructive sleep apnea in 2003. [8] [170] [171] It was approved in the UK in December 2002.
The drug reached phase 3 clinical trials for treatment of fatigue prior to the discontinuation of its development for this use in January 2024. [32] Aside from the preceding indications, armodafinil is currently under development for the treatment of eating disorders and, as of January 2024, is in phase 3 trials for this use. [32]
Modafinil is a drug that helps keep people awake and alert (wakefulness-promoting agent or "eugeroic"). [ 1 ] [ 2 ] Most of the listed modafinil analogues are drugs that specifically target dopamine reuptake (reabsorption of a neurotransmitter by a neurotransmitter transporter ) with stronger effects ( selective DRIs with improved potency ...
Eugeroics, in the sense of modafinil-type wakefulness promoting agents, include modafinil itself, armodafinil, and adrafinil, among others. [9] They are medically indicated for the treatment of certain sleep disorders , including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).
For premium support please call: 800-290-4726 more ways to reach us
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
The drug, suzetrigine, received the FDA's official stamp of approval Thursday to be sold as a 50-milligram prescription pill taken every 12 hours, according to a press release.
The drug has been found to block the dopamine transporter (DAT) by 83%, to a greater extent than methylphenidate without unfavorable concomitant adrenergic effects. [8] The drug is an atypical DRI similarly to modafinil. [11] [1] [9] The affinities for the DAT of flmodafinil's enantiomers and modafinil have also been studied.
Ad
related to: fda indications for modafinil 5 mg pill new appearance 2024goodrx.com has been visited by 100K+ users in the past month